Pharmacokinetics of vancomycin in adult cancer patients
- 16 December 2009
- journal article
- research article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 16 (4) , 245-250
Abstract
Background and Objectives. Gram-positive infections are prevalent among cancer patients and vancomycin therapy is often initiated empirically. A typical vancomycin pharmacokinetics is observed in such patients. The aim of the study was to evaluate the pharmacokinetics of vancomycin in this patient population and compare it to that of normal population. Method and Results. The pharmacokinetics of vancomycin was examined retrospectively in two groups of patients — 18 cancer patients (age 43.4 ± 22.1 years) and 13 patients without cancer (age 48.5 ± 20.2 years). Following the administration of intermittent intravenous infusion of 15 mg/kg of vancomycin, peak and trough vancomycin serum concentration were determined after the third dose or at steady state as per standard of care. Vancomycin data were analyzed according to a one-compartment open model. Pharmacokinetic parameters such as clearance (CL), volume of distribution (Vd), and K elimination (ke) were calculated. Both Vd and CL were significantly higher in the cancer group (Mean Vd was 70 ± 45 L in the cancer group and 31.1 ± 8.3 L in the noncancer group, p-value 0.002; CL mean was 110.1 ± 42 mL/min in the cancer group and 71.2 ± 22.2 mL/min in the noncancer group, p-value 0.005). There was no significant difference in K elimination and half-life (t1/2). Conclusion. Cancer patients may require higher than usual dosing regimens to ensure optimal therapeutic concentrations, since vancomycin CL and Vd is significantly higher in these patients, a dosing schedule as high as 60 mg/kg/day may be needed for cancer patients.Keywords
This publication has 26 references indexed in Scilit:
- Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases PharmacistsAmerican Journal of Health-System Pharmacy, 2009
- The epidemiology and treatment of infections in cancer patientsInternational Journal of Antimicrobial Agents, 2008
- A survey of the management of neutropenic fever in oncology units in the UKInternational Journal of Antimicrobial Agents, 2007
- Vancomycin: A 50-Year ReassessmentClinical Infectious Diseases, 2006
- The Pharmacokinetic and Pharmacodynamic Properties of VancomycinClinical Infectious Diseases, 2006
- The Role of Vancomycin in the Treatment ParadigmClinical Infectious Diseases, 2006
- Population Pharmacokinetic Analysis of Vancomycin in Patients with Hematological MalignanciesAntimicrobial Agents and Chemotherapy, 2005
- Current Trends in the Epidemiology of Nosocomial Bloodstream Infections in Patients with Hematological Malignancies and Solid Neoplasms in Hospitals in the United StatesClinical Infectious Diseases, 2003
- European Surveillance of Infections in Cancer Patients – ESICChemotherapy, 1999
- Pharmacokinetic parameters of vancomycin for therapeutic regimens in neutropenic adult patientsInternational Journal of Bio-Medical Computing, 1994